Valuation: Neurocrine Biosciences, Inc.

Capitalization 1.32TCr 1.12TCr 1.03TCr 975.51Cr 1.8TCr 1,22800Cr 1.84TCr 12TCr 4.74TCr 59TCr 4.95TCr 4.85TCr 2,09400Cr P/E ratio 2026 *
22.5x
P/E ratio 2027 * 18.2x
Enterprise value 982.65Cr 833.88Cr 764.31Cr 725.83Cr 1.34TCr 91TCr 1.37TCr 8.97TCr 3.53TCr 44TCr 3.69TCr 3.61TCr 1,55800Cr EV / Sales 2026 *
2.87x
EV / Sales 2027 * 3.53x
Free-Float
98.7%
Yield 2026 *
-
Yield 2027 * -
1 day-1.25%
1 week+4.17%
Current month-0.11%
1 month+3.06%
3 months-2.19%
6 months-6.89%
Current year-7.22%
1 week 127.76
Extreme 127.76
134.11
1 month 125.11
Extreme 125.11
134.2
Current year 122.14
Extreme 122.1375
142.82
1 year 100.83
Extreme 100.83
160.18
3 years 84.23
Extreme 84.23
160.18
5 years 71.88
Extreme 71.875
160.18
10 years 37.34
Extreme 37.345
160.18
Manager TitleAgeSince
Chief Executive Officer 53 11/10/2024
Director of Finance/CFO 47 01/11/2017
Chief Tech/Sci/R&D Officer 56 02/06/2025
Director TitleAgeSince
Director/Board Member 68 01/01/2008
Director/Board Member 64 01/04/1998
Chairman 78 01/05/2011
Change 5d. change 1-year change 3-years change Capi.($)
-1.25%+4.17%+29.80%+25.85% 1.32TCr
-0.77%-1.04%+9.52%+145.43% 82TCr
-1.49%-3.06%+46.50%+41.03% 56TCr
-2.24%-1.34%+17.76%+25.95% 36TCr
-0.91%+0.88%+25.20%+15.27% 33TCr
-1.06%-0.94%+45.74%+21.27% 31TCr
-1.65%-2.54%+50.13%+2.57% 29TCr
-0.83%-2.43%+29.42%+32.00% 29TCr
-1.45%+0.10%+26.28%+43.83% 19TCr
+0.15%+5.04%-33.71%-55.58% 18TCr
Average -0.77%+0.45%+24.66%+29.76% 33.45TCr
Weighted average by Cap. -0.75%-0.56%+25.43%+51.48%

Financials

2026 *2027 *
Net sales 342.91Cr 291Cr 266.72Cr 253.29Cr 468.11Cr 32TCr 478.09Cr 3.13TCr 1.23TCr 15TCr 1.29TCr 1.26TCr 54TCr 374.56Cr 317.85Cr 291.34Cr 276.67Cr 511.31Cr 35TCr 522.22Cr 3.42TCr 1.34TCr 17TCr 1.4TCr 1.38TCr 59TCr
Net income 61Cr 52Cr 48Cr 45Cr 84Cr 5.69TCr 85Cr 558.22Cr 219.55Cr 2.75TCr 229.47Cr 224.71Cr 9.7TCr 76Cr 65Cr 59Cr 56Cr 103.79Cr 7.07TCr 106Cr 693.8Cr 272.87Cr 3.41TCr 285.2Cr 279.28Cr 12TCr
Net Debt -338.03Cr -286.85Cr -262.92Cr -249.68Cr -461.44Cr -31TCr -471.28Cr -3.08TCr -1.21TCr -15TCr -1.27TCr -1.24TCr -54TCr -
Logo Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Employees
2,000
Date Price Change Volume
20/26/20 131.59 $ -1.25% 17,75,794
17/26/17 133.25 $ +3.77% 17,28,446
16/26/16 128.41 $ -2.31% 10,30,447
15/26/15 131.44 $ +0.48% 10,98,535
14/26/14 130.81 $ +3.55% 11,13,939
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
131.59USD
Average target price
186.45USD
Spread / Average Target
+41.69%

Quarterly revenue - Rate of surprise